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MaBACKGROUND Prior studies have shown that late gadolinium enhancement (LGE) by cardiac magnetic resonance
(CMR) can detect focal ﬁbrosis in aortic stenosis (AS), suggesting that it might predict higher mortality risk.
OBJECTIVES This study was conducted to evaluate whether LGE-CMR can predict post-operative survival in patients
with severe AS undergoing aortic valve replacement (AVR).
METHODS We prospectively evaluated survival (all-cause and cardiovascular disease related) according to LGE-CMR
status in 154 consecutive AS patients (96 men; mean age: 74  6 years) without a history of myocardial infarction un-
dergoing surgical AVR and in 40 AS patients undergoing transcatheter aortic valve replacement (TAVR).
RESULTS LGE was present in 29% of patients undergoing surgical AVR and in 50% undergoing TAVR. During a median
follow-up of 2.9 years, 21 patients undergoing surgical AVR and 20 undergoing TAVR died. In surgical AVR, the presence
of LGE predicted higher post-operative mortality (odds ratio: 10.9; 95% conﬁdence interval [CI]: 1.2 to 100.0; p ¼ 0.02)
and worse all-cause survival (73% vs. 88%; p ¼ 0.02 by log-rank test) and cardiovascular disease related survival
(85% vs. 95%; p ¼ 0.03 by log-rank test) on 5-year Kaplan-Meier estimates of survival after surgical AVR. Multivariate
Cox analysis identiﬁed the presence of LGE (hazard ratio: 2.8; 95% CI: 1.3 to 6.9; p ¼ 0.025) and New York Heart
Association functional class III/IV (hazard ratio: 3.2; 95% CI: 1.1 to 8.1; p < 0.01) as the sole independent predictors of
all-cause mortality after surgical AVR. The presence of LGE also predicted higher all-cause mortality (p ¼ 0.05) and
cardiovascular disease related mortality (p ¼ 0.03) in the subgroup of patients without angiographic coronary artery
disease (n ¼ 110) and higher cardiovascular disease related mortality in 25 patients undergoing transfemoral TAVR.
CONCLUSIONS The presence of LGE indicating focal ﬁbrosis or unrecognized infarct by CMR is an independent predictor
of mortality in patients with AS undergoing AVR and could provide additional information in the pre-operative evaluation
of risk in these patients. (J Am Coll Cardiol 2014;64:144–54) © 2014 by the American College of Cardiology Foundation.S evere degenerative aortic stenosis (AS) is themost frequent valvular heart disease in indus-trialized countries and its prevalence steadily
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145which may lead to alterations of both systolic and dia-
stolic left ventricular function (2,4,7,8) and functional
status (4) in patients with AS.3 Non severe AS,
2 severe AR,
2 severe MR,
1 subvalvular stenosis
3 Palliative balloon valvuloplasty (1 cancer, 2 amyloidosis)
40 TAVR
6 Ross surgery
13 Reoperation (12 CABG, 1 mitral repair)
9 Prior MI
1 Poor life expectancy (metastatic bladder cancer)
n=154
final study population
177 AVR
Other Rx
238 patients with AS
undergoing LGE-CMR
4 Poor LGE quality
FIGURE 1 Patient Selection
AR ¼ aortic regurgitation; AS ¼ aortic stenosis; AVR ¼ aortic valve replacement; CABG ¼
coronary artery bypass graft; CMR ¼ cardiac magnetic resonance; LGE ¼ late gadolinium;
MI ¼ myocardial infarction; MR ¼ mitral regurgitation.
SEE PAGE 155
AS = aortic stenosis
AVR = aortic valve
replacement
CAD = coronary artery disease
CMR = cardiac magnetic
resonance
LGE = late gadolinium
enhancement
LV = left ventricular
MI = myocardial infarction
TAVR = transcatheter aortic
replacementLate gadolinium-enhancement by cardiac mag-
netic resonance (LGE-CMR) is an attractive tech-
nique to noninvasively detect myocardial ﬁbrosis
and necrosis (9). Several studies have demonstrated
its ability to detect focal ﬁbrosis in the myocardium
of patients with AS (5,10,11). It has also been sug-
gested that such detection of LGE by CMR may
predict adverse outcomes in patients with AS (10,12)
and, therefore, that the technique might be useful
for pre-operative staging of risk in these patients.
Yet, studies evaluating post-operative survival of
patients with AS undergoing aortic valve replace-
ment (AVR) have involved only a small number of
patients.
In the present study, we sought to evaluate
whether the quantitative assessment of LGE by CMR
can predict survival in patients with severe AS un-
dergoing AVR. We studied 154 consecutive patients
with AS but without prior myocardial infarction (MI)
by LGE-CMR before AVR and used univariate and
multivariate survival analyses to identify predictors
of all-cause and cardiovascular disease related sur-
vival in these patients. An additional analysis was
performed in 40 patients undergoing transcatheter
aortic valve replacement (TAVR).
METHODS
PATIENT POPULATION. Patients age >50 years,
hospitalized for the pre-operative evaluation of
severe degenerative AS, deﬁned as an aortic valve
area of <1 cm2 or 0.6 cm2/m2 by transthoracic echo-
cardiography between February 2005 and November
2012 in our institution were approached for inclusion
in the study, after giving informed consent to the
institutional review board–approved study protocol.
Patients were not considered if they presented
with contraindications to CMR, such as the presence
of a pacemaker or deﬁbrillator or severe renal
dysfunction, deﬁned as a glomerular ﬁltration
rate <30 ml/min by the Cockcroft-Gault formula. In
this study, we evaluated survival in 154 patients with
severe AS, but without prior MI, undergoing surgical
AVR. We excluded patients having coexisting severe
aortic regurgitation, patients having severe mitral or
tricuspid valve disease requiring repair or replace-
ment of these valves, patients undergoing other
treatment for AS (such as Ross procedure); patientsundergoing AVR reoperation or having had
prior coronary surgery, and patients with
active malignancy or other conditions with a
life expectancy of <1 year discovered during
workup (Fig. 1). We also separately evaluated
survival in a subgroup of 40 patients under-
going TAVR.
CARDIAC MAGNETIC RESONANCE. Using a
1.5-T CMR system (Intera CV, Philips Health-
care, North Andover, Massachusetts), 10 to
12 consecutive short-axis images covering
the entire left ventricle (LV) were obtained.
Respectively, single 2-, 3-, and 4-chamber
long-axis images were acquired using a cine
steady-state free-precession sequence to allow for the
assessment of myocardial function and mass. About
10 to 15 min after the injection of 0.2 mmol/kg
gadolinium-based contrast agent, identical pre-
scriptions of short- and long-axis slices were acquired
using a 2- or 3-dimensional inversion recovery
sequence allowing for the assessment of LGE.
CMR images were analyzed using the freely avail-
able software Segment Version 1.8 (Medviso AB,
Lund, Sweden). LV volumes, ejection fraction (EF),
and regional wall thickness were obtained by semi-
automatic tracing of contours on the short-axis images
in end-diastole and end-systole, with manual correc-
tions when required (13). LGE by CMR was quantiﬁed
valve
TABLE 1 Baseline Characteristics of Patients Undergoing Surgical AVR
All
(n ¼ 154)
Without LGE
(n ¼ 110)
With LGE
(n ¼ 44) p Value
Demographics
Age, yrs 74  9 74  9 75  9 0.30 (NS)
Male 96 (62) 68 (62) 28 (64) 0.83 (NS)
Risk factors
Hypertension 96 (62) 70 (64) 26 (59) 0.60 (NS)
Hyperlipidemia 95 (62) 70 (64) 25 (57) 0.43 (NS)
Smoking history
Former smoker 40 (26) 31 (28) 9 (21) 0.32 (NS)
Current smoker 20 (13) 16 (12) 7 (16) 0.49 (NS)
Diabetes 35 (23) 20 (18) 15 (34) 0.03
Family history of CAD 31 (20) 22 (20) 9 (20) 0.95 (NS)
Symptoms
NYHA functional class III/IV 42 (27) 29 (26) 13 (30) 0.68 (NS)
Chest pain 31 (20) 22 (20) 9 (21) 0.95 (NS)
Syncope 11 (7) 6 (5) 5 (11) 0.35 (NS)
History/comorbidity
COPD 18 (12) 10 (9) 8 (18) 0.11 (NS)
PAD 16 (10) 11 (10) 5 (11) 0.98 (NS)
Stroke 15 (10) 9 (8) 6 (14) 0.46 (NS)
Prior PCI 5 (3) 3 (3) 2 (5) 0.62 (NS)
GFR, ml/min/m2 74  28 75  30 72  25 0.55 (NS)
Surgical risk
Logistic EuroSCORE I, % 7.1  5.5 7.0  5.7 7.6  4.9 0.53 (NS)
STS score, % 2.3  1.5 2.2  1.5 2.5  1.4 0.27 (NS)
ECG
AF 14 (9) 10 (9) 5 (9) 0.99 (NS)
LBBB 14 (8) 8 (7) 6 (14) 0.35 (NS)
Hemodynamics
SBP, mm Hg 134  20 134  21 135  20 0.77 (NS)
HR, beats/min 70  14 70  15 69  13 0.68 (NS)
Echocardiography
AVA, cm2 0.71  0.17 0.71  0.16 0.70  0.18 0.73 (NS)
AVAi, cm2/m2 0.38  0.09 0.38  0.08 0.38  0.09 0.96 (NS)
PG, mm Hg 79  25 80  25 77  28 0.47 (NS)
MG, mm Hg 49  17 49  16 47  18 0.56 (NS)
Angiography
CAD 44 (29) 31 (28) 13 (29) 0.87 (NS)
Vessels affected 1.7  0.8 1.6  0.7 1.9  1.2 0.48 (NS)
CMR
EDVi, ml/m2 81  25 79  24 83  27 0.40 (NS)
ESVi, ml/m2 35  25 33  23 41  28 0.07 (NS)
EF, % 60  15 61  14 55  18 0.05
Indexed LV mass, g/m2 95  25 93  22 99  31 0.18 (NS)
Values are mean  SD or n (%).
AF ¼ atrial ﬁbrillation; AVA ¼ aortic valve area; AVAi ¼ indexed aortic valve area; AVR ¼ aortic valve
replacement; CAD ¼ coronary artery disease; CMR ¼ cardiac magnetic resonance; COPD ¼ chronic obstructive
pulmonary disease; ECG ¼ electrocardiography; EDVi ¼ indexed end-diastolic volume; EF ¼ ejection fraction;
ESVi ¼ indexed end-systolic volume; GFR ¼ glomerular ﬁltration rate; HR ¼ heart rate; LBBB ¼ left bundle
branch block; LGE ¼ late gadolinium enhancement; LV ¼ left ventricular; MG ¼ mean transvalvular gradient;
NS ¼ nonsigniﬁcant; NYHA ¼ New York Heart Association; PAD ¼ peripheral arterial disease; PCI ¼ percutaneous
coronary intervention; PG ¼ peak transvalvular aortic gradient; SBP ¼ systolic blood pressure; STS ¼ Society of
Thoracic Surgery.
Barone-Rochette et al. J A C C V O L . 6 4 , N O . 2 , 2 0 1 4
Prognosis of LGE-CMR in Aortic Stenosis J U L Y 1 5 , 2 0 1 4 : 1 4 4 – 5 4
146with a fully automated method (14), and the results
were expressed as a percentage of myocardial mass.
The method automatically computes mean  SD ofsignal intensity in 5 sectors per slice. The region with
the lowest mean signal intensity is considered
“remote” myocardium, and LGE regions are consid-
ered >2.4 SD of remote. A fast-level, set algorithm and
correction for partial volume effects are used to limit
the heterogeneity of the hyper-enhanced regions
and to reduce the effect of noise of LGE detection.
Also, isolated LGE regions <1.5 ml are removed unless
they constitute >1% of LV volume or are the largest
LGE area in the image volume. The algorithm was
validated in an animal model of experimental infarc-
tion (14). LGE >1% myocardial mass (upper 95% con-
ﬁdence interval [CI] measured in a population of
40 healthy volunteers >50 years of age without
history of cardiovascular disease, all having normal
echocardiography, rest and exercise electrocardiog-
raphy, and coronary computed tomography without
signiﬁcant stenosis) was considered signiﬁcant. The
pattern of LGE was assessed by 2 independent ob-
servers whowere blinded to the clinical data, coronary
anatomy, and outcomes. Discordant ﬁndings were
resolved by consensus.
TRANSTHORACIC ECHOCARDIOGRAPHY. A stan-
dardized complete comprehensive transthoracic
echocardiography examination was performed
using an IE33 echocardiograph (Philips Healthcare)
equipped with a 3.5/1.75-MHz phased-array trans-
ducer, according to established guidelines (15). Im-
ages were re-analyzed off-line on Xcelera 1.2 LF 4
(Philips Healthcare) workstations by 2 observers, who
were blinded to the pre-operative and follow-up
clinical and CMR data. Multiple transducer positions
were used to record maximal instantaneous and
mean pressure gradients across the aortic valve.
Aortic valve area was computed using the continuity
equation. LV volumes and EF were computed using
the biplane Simpson method. LV mass was calculated
using the Devereux formula.
CORONARY ANGIOGRAPHY. Coronary angiography
was performed in all patients using the standard
Seldinger technique, and signiﬁcant coronary artery
disease (CAD) was considered >50% stenosis in ves-
sels >1.5 mm in diameter.
FOLLOW-UP. Survival status was obtained by phone
contact with patients, their relatives, or their physi-
cian. Patients’ history and treatment were retrieved
from medical ﬁles and from review of visit or hospital
records. Cause of death was categorized as cardiac or
noncardiac. Cardiovascular mortality was deﬁned as
death attributable to congestive heart failure (i.e.,
death preceded by acute worsening or exacerbation
of heart failure), MI, sudden death (i.e., unexpected,
unwitnessed or witnessed death in the absence of
TABLE 2 Patterns of LGE
Group No LGE Infarct LGE*
Noninfarct LGE
Focal Diffuse Septal Stripe
All patients (n ¼ 154) 110 (72) 14 (9) 20 (13) 7 (4) 3 (2)
No CAD (n ¼ 110) 79 (72) 8 (7) 16 (14) 4 (4) 3 (3)
CAD (n ¼ 44) 31 (71) 6 (14) 4 (9) 3 (7) 0 (0)
Values are n (%). *Subendocardial or transmural.
Abbreviations as in Table 1.
J A C C V O L . 6 4 , N O . 2 , 2 0 1 4 Barone-Rochette et al.
J U L Y 1 5 , 2 0 1 4 : 1 4 4 – 5 4 Prognosis of LGE-CMR in Aortic Stenosis
147other apparent causes) or as that occurring after
the AVR procedure.
STATISTICAL METHODS. Statistical analyses were
performed using SPSS version 21 (IBM SPSS Statistics,
IBM Corporation, Armonk, New York) software. All
tests were 2-sided, and p value <0.05 was considered
statistically signiﬁcant. Continuous variables are
expressed as mean  1 SD; categorical variables, as
counts and percents. Hazard ratios (HR) are expressed
as mean (95% CI). The interobserver reproducibility of
the measurement of LGE was evaluated using an
intraclass correlation coefﬁcient. Interobserver
concordance for the assessment of LGE patterns was
evaluated using the k test. The baseline characteristics
of the patients undergoing revascularization versus
medical treatment were compared using the chi-
square test or an unpaired Student t test. Survival in
patients with and without LGE was evaluated using
the Kaplan-Meier method and compared among
groups using the log-rank test. The index date was the
date of surgery.
The primary endpoint was all-cause mortality.
The secondary endpoint was cardiovascular disease
related mortality. In addition, we computed post-
operative mortality (deﬁned as 30-day or in-hospital
mortality), as well as late (>30-day) survival. All
clinical parameters were proposed for inclusion in a
univariate Cox proportional hazards model, and all
signiﬁcant (p < 0.10) univariate correlates of survival
were entered into a forward stepwise multivariate
Cox model.FIGURE 2 Examples of Different Patterns of LGE
(A) Absence of late gadolinium enhancement (LGE). (B to D) Noninfarct
predominantly affecting the left ventricular septum (C), and diffuse LGERESULTS
BASELINE CHARACTERISTICS OF PATIENTS UNDER-
GOING SURGICAL AVR. The baseline characteristics of
the 154 patients undergoing surgical AVR are sum-
marized in Table 1. Forty-four patients had signiﬁcant
CAD on coronary angiography. Using transthoracic
echocardiography, 25 patients (16%) were identiﬁed
as having AS with reduced EF (<50%). Among the 129
patients with preserved LVEF, 92 (60%) had high-
gradient AS and 37 (24%) had low-gradient AS.
PRE-OPERATIVE CMR. CMR was performed at a
median of 3 days (range 0 to 180 days) before surgery.
Interobserver concordance for the presence or absence
of LGE in patients was k ¼ 0.76. Forty-four patients
had signiﬁcant LGE (>1%). The mean percent of
myocardium affected by LGE in these patients was
3.5  2.3%. Table 1 compares the characteristics of
patients with and without LGE. LGE was more preva-
lent in patients with diabetes mellitus. EF was less inpatterns: Focal nodular noninfarct LGE (B), linear midwall LGE
pattern (D). (E) Typical transmural infarct-type pattern.
TABLE 3 Characteristics of Survivors Versus Nonsurvivors
Survivors
(n ¼ 137)
Nonsurvivors
(n ¼ 21) p Value
Demographics
Age, yrs 74  9 76  6 0.15 (NS)
Male 80 (60) 16 (76) 0.16 (NS)
Risk factors
Hyperlipidemia 83 (62) 12 (57) 0.65 (NS)
Hypertension 80 (60) 16 (76) 0.16 (NS)
Smoking history
Former smoker 32 (24) 8 (38) 0.17 (NS)
Current smoker 18 (14) 2 (10) 0.87 (NS)
Diabetes 31 (23) 4 (19) 0.88 (NS)
Family history of CAD 27 (20) 4 (19) 0.89 (NS)
Symptoms
NYHA functional class III/IV 31 (24) 11 (54) 0.005
Chest pain 29 (22) 2 (10) 0.32 (NS)
Syncope 9 (7) 2 (9) 0.65 (NS)
History/comorbidity
COPD 14 (10) 4 (19) 0.27 (NS)
PAD 14 (10) 2 (10) 0.99 (NS)
Stroke 14 (10) 1 (5) 0.69 (NS)
Prior PCI 3 (2) 2 (9) 0.14 (NS)
GFR, ml/min/m2 76  29 65  17 0.03
Surgical risk
Logistic EuroSCORE I, % 6.9  5.6 8.6  4.9 0.18 (NS)
STS score, % 2.3  1.5 2.6  1.3 0.30 (NS)
ECG
AF 13 (10) 1 (5) 0.69 (NS)
LBBB 10 (7) 4 (19) 0.11 (NS)
Echocardiography
AVAi, cm2/m2 0.38  .09 0.38  .07 0.99 (NS)
PG, mm Hg 80  25 74  23 0.31 (NS)
MG, mm Hg 49  17 45  15 0.29 (NS)
Type of surgery
Stented bioprosthesis 109 (82) 17 (81) 0.88 (NS)
Stentless bioprosthesis 18 (14) 4 (19) 0.68 (NS)
Mechanical valve 6 (5) 0 0.60 (NS)
Valve size, mm 24  2 24  0.2 0.78 (NS)
Associated CABG 35 (26) 9 (43) 0.12 (NS)
CMR
EDVi, ml/m2 80  25 82  24 0.74 (NS)
ESVi, ml/m2 35  25 37  26 0.76 (NS)
EF, % 60  15 59  17 0.80 (NS)
Ind. LV mass, g/m2 93  23 101  33 0.22 (NS)
Values are mean  SD or n (%).
CABG ¼ coronary artery bypass grafting; other abbreviations as in Table 1.
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148patients with LGE than in those without LGE. All
other parameters, and in particular the severity of
AS, and the prevalence of CAD were not signiﬁcantly
different among the 2 groups. LGE was considered
infarct type if its location was subendocardial or
transmural; otherwise, it was considered noninfarct
type (Table 2, Fig. 2). Noninfarct patterns were
focal lines (septal stripe), focal spots, or diffuseareas of LGE in midventricular or epicardial location.
Prevalence and patterns of LGE were not signiﬁ-
cantly different among patients with and without
CAD.
SURGERY. AVR was performed using a bioprosthesis
in 148 patients (96%) (126 stented and 22 stentless
valves) and using a mechanical valve in 6 patients
(4%). One hundred ten patients underwent isolated
AVR, whereas 44 patients received associated coro-
nary artery bypass grafting. The mean number of
coronary artery bypass grafts was 1.8  0.8, including
80% left internal mammary grafts. Postoperative
echocardiography demonstrated correct function of
the prosthesis, without patient–prosthesis mismatch,
in all patients.
EVENTS AFTER SURGICAL AVR. Over a median
follow-up of 2.9 years (100% complete), 21 patients
died, 11 of cardiovascular disease related causes. Five
of those 11 were post-operative deaths that occurred
within 30 days after AVR or during hospitalization,
including 3 sudden deaths, 1 related to post-operative
heart failure, and 1 due to perioperative stroke. Six of
the 11 cardiovascular disease related deaths occurred
after 30 days, including 3 sudden deaths, 1 due to
heart failure, 1 due to infective endocarditis, and 1
due to aneurysm rupture. The 10 noncardiac deaths
were caused by cancer (n ¼ 7), sepsis (n ¼ 1), cerebral
hemorrhage after an accidental fall (n ¼ 1), and sui-
cide (n ¼ 1).
LGE AND PREDICTION OF SURVIVAL IN PATIENTS
UNDERGOING SURGICAL AVR. The clinical charac-
teristics of the patients according to survival are
shown in Table 3. Univariate and multivariate pre-
dictors of all-cause survival after AVR are shown in
Table 4. The presence of LGE, New York Heart Asso-
ciation (NYHA) functional class III/IV, and the pres-
ence of left bundle branch block were the
sole predictors of all-cause survival. Multivariate Cox
analysis demonstrated that the presence of LGE
and NYHA functional class were the only indepen-
dent determinants of all-cause survival. Also, for
cardiovascular disease related survival, the presence
of LGE was the sole predictor on multivariate Cox
analysis. Kaplan-Meier curves for all-cause and car-
diovascular disease related survival, according to pre-
operative LGE status, are shown in Figure 3. Patients
with pre-operative LGE had signiﬁcantly worse all-
cause and cardiovascular disease related survival
than did patients without LGE. This resulted mainly
from higher post-operative mortality (OR: 10.9; 95%
CI: 1.18 to 100; p ¼ 0.02), whereas the risks for late all-
cause mortality (p ¼ 0.25 by log-rank test) and car-
diovascular disease related mortality (p ¼ 0.60 by
TABLE 4 Predictors of Overall Survival After Surgical AVR on Univariate and
Multivariate Cox Analysis
Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value
Presence of LGE 2.8 (1.1–6.7) 0.02 2.8 (1.1–6.9) 0.025
NYHA functional class III/IV 3.2 (1.3–8.0) 0.007 3.2 (1.1–8.1) 0.01
LBBB 2.8 (0.92–8.3) 0.06 – –
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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FIGURE 3 Kaplan-Meier Survival in Patients With AS Undergoing Surgical AVR,
by LGE Status
All-cause (A) and cardiovascular disease related (B) survival in 154 patients undergoing
surgical aortic valve replacement (AVR), according to the presence or absence of late
gadolinium enhancement (LGE) pre-operatively detected by cardiac magnetic resonance
(CMR). Kaplan-Meier graphs show that patients without LGE had greater all-cause and
cardiovascular survival than did patients with LGE.
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149log-rank test) were not signiﬁcantly increased. The
presence of LGE also remained a signiﬁcant predictor
of increased all-cause and cardiovascular disease
related mortality (p ¼ 0.05 and p ¼ 0.03, respectively,
by log-rank test) if we considered only patients
without CAD (Fig. 4).
CHARACTERISTICS AND SURVIVAL OF PATIENTS
UNDERGOING TAVR. TAVR patients were signiﬁcantly
older, had higher comorbidities, a higher NYHA
functional class, a lower glomerular ﬁltration rate, a
lower EF, and more severe CAD than did patients
undergoing conventional AVR (Table 5). Also, they
often had a history of MI or cardiac surgery, and LGE
was present more frequently in patients undergoing
TAVR (20 of 40 [50%]; p ¼ 0.005) than in patients
undergoing surgical AVR. TAVR was performed using
the Sapien valve (Edwards Lifesciences Corporation,
Irvine, California), by transfemoral access in 25 pa-
tients and by transapical access in 15 patients. Median
follow-up after TAVR was 3.9 years. During this
period, 20 patients died, 15 of cardiovascular causes.
In the subgroup of 25 patients undergoing trans-
femoral TAVR (Fig. 5), the presence of LGE was
associated with signiﬁcantly worse (p ¼ 0.045) car-
diovascular disease related survival and a trend for a
lower but statistically nonsigniﬁcant difference (p ¼
0.09) all-cause survival. By contrast, survival in the 15
patients undergoing transapical TAVR was not pre-
dicted by LGE. Indeed, this probably occurred
because these patients had signiﬁcantly higher peri-
operative mortality (25% vs. 0% in transfemoral
TAVR; p ¼ 0.04), likely reﬂecting higher comorbidity
and an early learning curve with the transapical
technique.
DISCUSSION
Our study revealed that in patients with severe AS
without a history of MI undergoing surgical AVR, the
presence and extent of myocardial focal ﬁbrosis and
necrosis detected by LGE-CMR predict increased
perioperative risk and worse all-cause and cardio-
vascular disease related survival. This was also true in
patients without angiographically signiﬁcant CAD.
We also observed that LGE can predict higher car-
diovascular disease related mortality risk after
transfemoral TAVR.
FIBROSIS AND LGE-CMR IN AS. In response to the
chronic pressure overload of severe AS, the LV reacts
by compensatory concentric hypertrophic remodel-
ing. This phenomenon involves not only increased
myocyte volume but also coordinated remodeling and
increased extracellular matrix (16). By histopathology,
hearts with severe AS present with both interstitial
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FIGURE 4 Kaplan-Meier Survival in Patients With AS Without CAD Undergoing
Surgical AVR, by LGE Status
All-cause (A) and cardiovascular disease related (B) survival in a subgroup of 110 patients
without angiographically detected coronary artery disease (CAD) undergoing surgical AVR,
according to the presence or absence of LGE pre-operatively detected by CMR. Kaplan-
Meier graphs show that patients without LGE had greater all-cause and cardiovascular
survival than did patients with LGE. Abbreviations as in Figure 3.
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150diffuse reactive ﬁbrosis as well as focal replacement
ﬁbrosis (2–5). Diffuse ﬁbrosis appears to result from
alterations in the balance of matrix metal-
loproteinases and their speciﬁc tissue inhibitors (3)
subsequent to the overstimulation of the
angiotensin-renin system (17) (Central Illustration).
Replacement ﬁbrosis involves myocyte death by
apoptosis or necrosis. This can occur in a direct
response to the mechanical forces associated with
increased afterload or from the effects of myocardial
ischemia (6), due either to CAD, a coexisting conditionpresent in a substantial proportion of patients with
AS, or to imbalance between reduced myocardial
supply resulting from decreased coronary perfusion
pressure and increased myocardial metabolic demand
subsequent to the increased LV workload in severe
AS (18,19). Indeed, a direct association between the
magnitude of ischemia and the development of
ﬁbrosis in AS has been described (19).
LGE-MRI is the technique of choice to non-
invasively detect myocardial ﬁbrosis and necrosis
in the myocardium (9). Indeed, gadolinium-based
contrast agents have extravascular distribution vol-
ume, which increases when the extracellular matrix
proliferates or when myocytes are replaced by focal
ﬁbrosis. Imaging performed several minutes after a
gadolinium injection, when the contrast agent has
equilibrated with the blood, can therefore reveal
focal areas of intramyocardial ﬁbrosis as bright areas
of gadolinium accumulation relative to normal
tissue. Although the detection of LGE is likely a
measurement of focal replacement ﬁbrosis and is
less sensitive for diffuse interstitial ﬁbrosis, several
studies have indicated a good correlation between
the size of the LGE by MRI and histologically
measured ﬁbrosis (4,5,10) in AS. Our present study
used an automated-analysis method for the quanti-
ﬁcation of LGE, with high reproducibility, which was
validated in animals against histology (14). Similar to
previous studies (5,10,11), we found that LGE indi-
cating focal replacement ﬁbrosis occurs in approxi-
mately 30% of patients with AS and may present in
different distribution patterns, either mirroring
typical ischemic LGE or in focal and diffuse non-
ischemic patterns. Because we did not perform his-
topathology in our patients, we can only speculate
on the underlying pathophysiological mechanisms of
macroscopically detected LGE by MRI. Sub-
endocardial infarct-type LGE might represent un-
recognized infarcts but also could result from
longstanding ischemia due to oxygen supply–de-
mand mismatch in severe AS. Focal spots of LGE
could result from distal microembolization or
represent areas of more dense replacement ﬁbrosis,
similar to midwall LGE. Diffuse LGE patterns likely
result from increased gadolinium distribution vol-
ume in areas with diffuse histological interstitial
ﬁbrosis.
IMPLICATIONS OF FIBROSIS IN AS ON LV FUNCTION
AND OUTCOME. Our study conﬁrms the previously
reported association of LGE with LV dysfunction
(4,5,8,10). Indeed, patients with LGE had slightly
lower EF than patients without LGE. More impor-
tantly, we showed that high amounts of LGE by CMR
TABLE 5 Characteristics of Patients Undergoing TAVR
All TAVR
(n ¼ 40)
TAVR (n ¼ 40)
p Value
All TAVR vs.
Surgical AVR
Transfemoral
(n ¼ 25)
Transapical
(n ¼ 15)
Demographics
Age, yrs 83  5 83  5 84  4 <0.001
Male 23 (58) 17 (67) 6 (40) 0.18 (NS)
Risk factors
Hypertension 28 (70) 14 (56) 14 (93) 0.04
Hyperlipidemia 22 (55) 11 (44) 11 (74) 0.14 (NS)
Smoking history
Former smoker 14 (35) 9 (36) 5 (33) 0.52 (NS)
Current smoker 4 (10) 3 (12) 1 (7) 0.92 (NS)
Diabetes 10 (25) 7 (28) 3 (20) 0.81 (NS)
Family history of CAD 7 (17) 5 (16) 2 (13) 0.84 (NS)
Symptoms
NYHA functional class III/IV 23 (57) 14 (56) 9 (60) <0.001
Chest pain 6 (15) 4 (16) 2 (13) 0.84 (NS)
Syncope 2 (5) 2 (8) 0 0.75 (NS)
History/comorbidity
PAD 20 (50) 5 (20) 15 (100) <0.001
Prior CABG 17 (42) 8 (32) 9 (60) <0.001
Prior MI 10 (25) 5 (20) 5 (33) <0.001
Prior PCI 10 (25) 7 (28) 3 (20) <0.001
Stroke 10 (25) 5 (20) 5 (33) 0.02
COPD 1 (3) 0 1 (6) 0.17 (NS)
GFR, ml/min/m2 48  19 52  20 42  14 <0.001
Surgical risk
Logistic EuroSCORE I, % 26  17 25  17 29  16 <0.001
STS score, % 9.1  5.6 7.9  6.0 11.0  4.4 <0.001
ECG
AF 12 (30) 6 (24) 6 (40) <0.001
LBBB 10 (25) 6 (24) 4 (27) 0.02
Hemodynamics
SBP, mm Hg 138  25 134  26 145  21 0.17 (NS)
HR, beats/min 72  17 71  15 73  19 0.73 (NS)
Echocardiography
AVA, cm2 0.65  0.118 0.64  0.15 0.67  0.23 0.24 (NS)
AVAi, cm2/m2 0.36  0.10 0.35  0.08 0.38  0.12 0.37 (NS)
PG, mm Hg 64  20 63  20 67  22 0.003
MG, mm Hg 40  13 40  12 40  16 0.02
Angiography
CAD 27 (67) 16 (64) 11 (70) <0.001
Vessels affected 2.0  0.9 1.8  0.7 2.3  1.0 0.07 (NS)
CMR
EDVi, ml/m2 89  23 92  24 83  21 0.08 (NS)
ESVi, ml/m2 46  26 51  28 39  19 0.01
EF, % 50  17 46  17 55  15 <0.001
Ind. LV mass, g/m2 98  18 96  19 101  16 0.58 (NS)
Values are mean  SD or n (%).
Abbreviations as in Tables 1 and 3.
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151predicted worse all-cause and cardiovascular disease
related survival after AVR. This is consistent with
ﬁndings from a recent study that demonstrated that
histopathologically measured ﬁbrosis is associated
with poorer outcomes in patients after AVR (20).
Another study reported high post-operative mortality
among 58 patients with high amounts of histopath-
ological ﬁbrosis; however, it was not powered to
demonstrate statistical signiﬁcance (4). Other CMR
studies have suggested that LGE is a predictor of
survival in patients with AS. In a prospective registry
evaluating 143 patients with AS who underwent CMR
with LGE, Dweck et al. (12) reported that midwall
ﬁbrosis predicted worse survival. Yet, this study also
included patients with moderate AS, only 50% of
whom underwent AVR, whereas the remaining pa-
tients remained under medical treatment. The same
authors also assessed 63 patients with severe AS
undergoing AVR, reporting that patients with LGE
had more post-operative major cardiac events than
patients without LGE. However, due to the small
size of the study population, they were not able to
demonstrate a statistically signiﬁcant difference in
mortality (21). So far, only the study by Azevedo
et al. (10) has demonstrated that pre-operative LGE
can predict post-operative survival in patients un-
dergoing AVR. However, it was performed in a
mixed population of 54 patients undergoing AVR for
either AS or aortic regurgitation and included only
28 patients with AS. Also, in the present study, the
post-operative mortality rate in these patients was
higher (6.8% vs. 4.7% per year), probably due to the
fact that surgery was performed at a very advanced
stage of valve disease.
Our study is the largest study to date to have
evaluated the prognostic value of LGE-CMR on
perioperative and long-term survival after surgical
AVR for severe AS, and is the ﬁrst study limited to
patients with severe AS only. We studied a group of
patients with overall low pre-operative risk, as pre-
dicted by Society of Thoracic Surgery and Euroscore
risk scores, low observed operative mortality (3.2 %),
and good long-term survival (mean: 84% at 5 years)
after AVR, consistent with survival reported in large
registries. Despite low perioperative risk and good
long-term outcome, we found that LGE-CMR was by
far the strongest predictor of all-cause and cardio-
vascular disease related mortality both on univariate
and multivariate analyses. Interestingly, in our
study, the majority of cardiovascular deaths were
sudden, suggesting that the presence of LGE in-
creases the risk for sudden cardiac death. This is
consistent with observations in other conditions,
such as ischemic heart disease (22) and dilated(23,24) and hypertrophic cardiomyopathy (25,26), in
which the presence of LGE has been shown to be an
arrhythmogenic substrate and directly linked to the
development of arrhythmia and sudden cardiac
death (27,28). We also report for the ﬁrst time that
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FIGURE 5 Kaplan-Meier Survival in Patients Without CAD Undergoing Transfemoral
TAVR, by LGE Status
All-cause (A) and cardiovascular disease free (B) survival in a subgroup of 25 patients un-
dergoing transfemoral transcatheter AVR (TAVR), according to the presence or absence of
LGE pre-operatively detected by CMR. Kaplan-Meier graphs show that patients without LGE
had similar all-cause survival and greater cardiovascular disease related survival than did
patients with LGE.
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152LGE may predict cardiovascular disease related sur-
vival after TAVR.
CLINICAL IMPLICATIONS. Currently, the clinical
management of patients with AS is based mainly on
the assessment of valvular parameters, EF, and
symptoms (29). Because the appearance of symp-
toms identiﬁes a critical point in the natural history
of AS, and because AVR not only results in symp-
tomatic relief but also improves LV function and
survival, the most recent European Society of
Cardiology and American College of Cardiology/American Heart Association guidelines (30,31)
consider severe, symptomatic AS and AS with
reduced EF as class I indications for surgery. How-
ever, when surgery is performed at this point—when
patients have become symptomatic and in the
setting of low EF—surgical risk is increased and
long-term survival may be compromised, which is
supported by the ﬁndings of the present study.
Therefore, it may be better to offer surgery at an
earlier time, when patients are still asymptomatic.
The work by Dweck et al. (12) suggests that the
presence of LGE identiﬁes a higher risk for death
in medically treated patients. Our ﬁndings support
that identiﬁcation of primary structural abnormal-
ities of the LV myocardium by LGE-CMR also pre-
dicts mortality in patients after surgery, suggesting
the technique could potentially be useful for timing
of surgery and for selecting the operative approach.
Indeed, the absence of LGE-CMR in patients with
severe AS appears to identify patients at low risk
for surgery, with excellent long-term survival, who
might beneﬁt from early surgery. On the other hand,
patients with high degrees of LGE, indicating higher
post-operative risk and lower survival, could be
candidates for TAVR instead of classic AVR, although
we also found that LGE predicted worse outcome after
transfemoral TAVR. Furthermore, the high risk for
sudden cardiac death in patients with LGE suggests
that they could potentially beneﬁt from prophy-
lactic implantation of an implantable cardioverter-
deﬁbrillator device to improve long-term survival.
These ﬁndings need to be conﬁrmed by larger studies.
STUDY LIMITATIONS. Although our study is the
largest to date, its power was limited by a modest
number of events. This bears a risk of overﬁtting in
multivariable models. Because we excluded patients
with contraindications to CMR, and in particular renal
failure, our conclusions cannot be extrapolated to all
patients with severe AS. In this study, we used
LGE-CMR, which assesses replacement ﬁbrosis. More
recently, it was shown that the measurement of
myocardial extravascular volume fraction (32) by T1
mapping can estimate diffuse interstitial reactive
ﬁbrosis. Unfortunately, this technique was not yet
available at the time of the study, and, therefore, we
did not evaluate diffuse ﬁbrosis in this work. We did
not perform endomyocardial biopsy, the current
reference standard for the assessment of myocardial
ﬁbrosis, nor did we measure B-type natriuretic pep-
tide or global LV strain, which also have been recog-
nized as novel predictors of events in patients with
AS (33). Finally, our study focused only on survival,
whereas functional status and clinical improvement
CENTRAL ILLUSTRATION Pathophysiology of Myocardial Fibrosis in Aortic Stenosis
In response to the chronic pressure overload of severe aortic stenosis, the left ventricle reacts by compensatory concentric hypertrophic remodeling. This phenomenon
involves not only increased myocyte volume (second panel from the left) but also coordinated remodeling and increased extracellular matrix, with development of both
diffuse interstitial and focal replacement ﬁbrosis. Diffuse interstitial ﬁbrosis consists of increased deposition of collagen in interstitial spaces (third panel from the left).
Focal replacement ﬁbrosis consists of replacement of myocytes by ﬁbrotic tissue (right panel). This latter form of ﬁbrosis can be detected by late gadolinium
enhancement on cardiac magnetic resonance.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: Chronic left
ventricular afterload excess in patients with AS leads to left
ventricular hypertrophy and ﬁbrosis.
COMPETENCY IN MEDICAL KNOWLEDGE 2: LGE-CMR can
detect both diffuse interstitial and focal replacement ﬁbrosis.
COMPETENCY IN PATIENT CARE: The optimal timing of
AVR in asymptomatic patients with AS is controversial. The
detection of focal replacement ﬁbrosis by LGE-CMR identiﬁes
those at higher risk for adverse short-term outcomes after
either surgical or transcatheter AVR.
TRANSLATIONAL OUTLOOK: Larger and longer-term
studies need to conﬁrm the clinical utility of LGE-CMR ﬁnd-
ings in identifying asymptomatic patients with severe AS most
likely to beneﬁt from prophylactic AVR.
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153might be other important outcomes to consider in
AVR patients.
CONCLUSIONS
Our study shows that the detection of LGE by CMR
can predict all-cause and cardiovascular disease
related mortality in low-risk patients with severe AS
without a history of MI undergoing surgical AVR. It
also appears to predict cardiovascular disease related
mortality in high-risk patients undergoing trans-
femoral AVR. Therefore, the evaluation of LGE could
be a new method of risk stratiﬁcation in patients with
AS undergoing AVR.
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